<doc>
  <docmeta id="113s908is">
    <bill congress="113" type="s" number="908" version="is"/>
    <revision size="21002" annotations="0" status="complete" id="4" commit-time="2013-08-05T22:31:31Z" committer="mbohmer" doc="113s908is/4.xml">
      <description>Edited via AKN</description>
    </revision>
  </docmeta>
  <bill bill-stage="Introduced-in-Senate" public-private="public">
	<metadata>
<dublinCore>
<title>113 S908 IS: Hereditary Hemorrhagic Telangiectasia Diagnosis and Treatment Act of 2013</title>
<publisher>U.S. Senate</publisher>
<date>2013-05-08</date>
<format>text/xml</format>
<language>EN</language>
<rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</rights>
</dublinCore>
</metadata>
<form>
		<distribution-code display="yes">II</distribution-code>
		<congress>113th CONGRESS</congress>
		<session>1st Session</session>
		<legis-num>S. 908</legis-num>
		<current-chamber>IN THE SENATE OF THE UNITED STATES</current-chamber>
		<action>
			<action-date date="20130508">May 8, 2013</action-date>
			<action-desc>
        <sponsor name-id="S257">Mr. Johnson of South
			 Dakota</sponsor> introduced the following bill; which was read twice and
			 referred to the <committee-name committee-id="SSHR00">Committee on Health,
			 Education, Labor, and Pensions</committee-name>
      </action-desc>
		</action>
		<legis-type>A BILL</legis-type>
		<official-title>To amend the Public Health Service Act to improve the
		  diagnosis and treatment of hereditary hemorrhagic telangiectasia, and for other
		  purposes.</official-title>
	</form>
	<legis-body id="H43AED9041C054519B249E85471D68E8F" style="OLC">
		<section id="HC5D3CC6473C3465492173AFC9A70264E" section-type="section-one">
      <enum>1.</enum>
      <header>Short title</header>
      <text display-inline="no-display-inline">This Act may be cited as the
			 <quote>
          <short-title>Hereditary Hemorrhagic Telangiectasia
			 Diagnosis and Treatment Act of 2013</short-title>
        </quote>.</text>
		</section>
    <section id="HC22FDD20A44B489B991DD261B83630C3">
      <enum>2.</enum>
      <header>Findings</header>
      <text display-inline="no-display-inline">The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="0001">Congress</cato:entity-ref> finds as follows:</text>
			<paragraph id="H8476827151194AB3B050049B75DA95DB">
        <enum>(1)</enum>
        <text>Hereditary
			 hemorrhagic telangiectasia (referred to in this section as <quote>HHT</quote>)
			 is a largely undiagnosed or misdiagnosed vascular genetic bleeding disorder
			 resulting in artery-vein malformations (referred to in this section as
			 <quote>AVMs</quote>), which lead to preventable, catastrophic and disabling
			 consequences. HHT can cause sudden death at any age, unless detected and
			 treated. Early detection, screening, and use of readily available treatment can
			 prevent premature deaths and long-term health complications resulting from HHT.
			 A person with HHT has the tendency to form blood vessels that lack the
			 capillaries between an artery and vein. HHT often results in spontaneous
			 hemorrhage or stroke from brain or lung AVMs. In addition to hemorrhagic
			 stroke, embolic stroke and brain abscess occur in approximately 30 percent of
			 individuals with HHT AVMs in the lung (due to lack of capillaries between the
			 arterial and venous systems that normally filter out clots and
			 bacteria).</text>
			</paragraph>
      <paragraph id="H194C672EED0F43FDA2D7E429F1114AE2">
        <enum>(2)</enum>
        <text>One in 5,000
			 American children and adults suffer from HHT.</text>
			</paragraph>
      <paragraph id="H7C704CE9923A4A3BB8E0E7D65A36E4EE">
        <enum>(3)</enum>
        <text>Studies have found
			 an increase in morbidity and mortality rates for individuals who suffer from
			 HHT.</text>
			</paragraph>
      <paragraph id="HA4AC377F112A497B890296E921F50D08">
        <enum>(4)</enum>
        <text>Due to the
			 widespread lack of knowledge, accurate diagnosis, and appropriate intervention,
			 90 percent of HHT-affected families are at risk for preventable
			 life-threatening and disabling medical incidents such as stroke.</text>
			</paragraph>
      <paragraph id="H30495AD82BE34A36B2028FC111627482">
        <enum>(5)</enum>
        <text>Early detection,
			 screening, and treatment can prevent premature deaths, spontaneous hemorrhage,
			 hemorrhagic stroke, embolic stroke, brain abscess, and other long-term health
			 care complications resulting from HHT.</text>
			</paragraph>
      <paragraph id="ID13a81f4fad504e67a68014be98b058c2">
        <enum>(6)</enum>
        <text>HHT is an
			 important health condition with serious health consequences which are amenable
			 to early identification and diagnosis with suitable tests, and acceptable and
			 available treatments in established treatment centers.</text>
			</paragraph>
      <paragraph id="IDc6101c45657d48f794623b3acea27b38">
        <enum>(7)</enum>
        <text>Timely
			 identification and management of HHT cases is an important public health
			 objective because it will save lives, prevent disability, and reduce direct and
			 indirect health care costs expenditures. A recent study has found use of a
			 genetic testing model for HHT diagnosis saves $9,900,000 if screening is
			 limited to individuals within the family groups that have the gene defect,
			 leading to early intervention in individuals found to have treatable
			 AVMs.</text>
			</paragraph>
      <paragraph id="HC4208270CBDF42B7A614B19735F0E30E">
        <enum>(8)</enum>
        <text>Without a new
			 program for early detection, screening, and treatment, 14,000 children and
			 adults who suffer from HHT in the population today will suffer premature death
			 and disability.</text>
			</paragraph>
    </section>
    <section id="H83689FDDCF244E09AE3C6E13707344FA">
      <enum>3.</enum>
      <header>Purpose</header>
      <text display-inline="no-display-inline">The purpose of this Act is to create a
			 federally led and financed initiative for early diagnosis and appropriate
			 treatment of hereditary hemorrhagic telangiectasia that will result in the
			 reduction of the suffering of families, prevent premature death and disability,
			 and lower health care costs through proven treatment interventions.</text>
		</section>
    <section id="H5AE677CE15A847538D07875FA6D0EE37">
      <enum>4.</enum>
      <header>National
			 Institutes of Health</header>
      <text display-inline="no-display-inline">
        <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
          <cato:entity-ref entity-type="act" value="Public Health Service Act/t:IV/pt:B">Part B of
			 title IV of the Public Health Service Act</cato:entity-ref> (<external-xref legal-doc="usc" parsable-cite="usc/42/284">
            <cato:entity-ref entity-type="uscode" value="usc/42/284/etseq">42 U.S.C. 284 et seq.</cato:entity-ref>
          </external-xref>)</cato:entity> is amended by
			 adding at the end the following:</text>
			<quoted-block display-inline="no-display-inline" id="H9E3BA9014B194079B18601934E089359" style="OLC">
				<section id="H7FC26F590EF54DF5AB9DC2E9526FE82D">
          <enum>409K.</enum>
          <header>Hereditary
				hemorrhagic telangiectasia</header>
					<subsection id="H2269E55FD3914521B493299A17C3E217">
            <enum>(a)</enum>
            <header>HHT
				Initiative</header>
						<paragraph id="H53BC3FF7967B44C1B45D76534465971E">
              <enum>(1)</enum>
              <header>Establishment</header>
              <text>The
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall establish and implement an HHT initiative to assist in
				coordinating activities to improve early detection, screening, and treatment of
				people who suffer from HHT. Such initiative shall focus on—</text>
							<subparagraph id="HC025E5CA4ABE470280BA0A377A9CE383">
                <enum>(A)</enum>
                <text>advancing research
				on the causes, diagnosis, and treatment of HHT, including through the conduct
				or support of such research; and</text>
							</subparagraph>
              <subparagraph id="H476E090B4E92411C9427EE3E390FA425">
                <enum>(B)</enum>
                <text>increasing
				physician and public awareness of HHT.</text>
							</subparagraph>
            </paragraph>
            <paragraph id="HDB1935F225B0441A803B5E778DBFE954">
              <enum>(2)</enum>
              <header>Consultation</header>
              <text>In
				carrying out this subsection, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall consult with the Director of
				the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7529">National Institutes of Health</cato:entity-ref> and the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7523">Director of the Centers for Disease
				Control and Prevention</cato:entity-ref>.</text>
						</paragraph>
          </subsection>
          <subsection id="H62C7139DD55C4A409A12B9E72D2B614D">
            <enum>(b)</enum>
            <header>HHT Coordinating
				Committee</header>
						<paragraph id="H54805EA69994462BBB04D5BD70705BAC">
              <enum>(1)</enum>
              <header>Establishment</header>
              <text>Not
				later than 60 days after the date of the enactment of this section, the
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref>, in consultation with the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7529">Director of the National Institutes of
				Health</cato:entity-ref>, shall establish a committee to be known as the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" value="HHT Coordinating Committee" entity-parent-id="7529" proposed="true">HHT Coordinating
				Committee</cato:entity-ref>.</text>
						</paragraph>
            <paragraph id="H3A75B0DB3B26481B85C89D1AF8C4AAF7">
              <enum>(2)</enum>
              <header>Membership</header>
							<subparagraph id="H4999660EAA54405AA9258D7334CDEBB4">
                <enum>(A)</enum>
                <header>In
				general</header>
                <text display-inline="yes-display-inline">The members of the
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" value="HHT Coordinating Committee" entity-parent-id="7529" proposed="true">Committee</cato:entity-ref> shall be appointed by the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref>, in consultation with the
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7529">Director of the National Institutes of Health</cato:entity-ref>, and shall consist of 12
				individuals who are experts in HHT or arteriovenous malformation (AVM) as
				follows:</text>
								<clause id="HCC5B0A9F9B0A4006A7A0E7B9D99E3B7E">
                  <enum>(i)</enum>
                  <text display-inline="yes-display-inline">Four representatives of HHT Treatment
				Centers of Excellence designated under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Public Health Service Act/s:317U/ss:c/p:1" proposed="true">section 317U(c)(1)</cato:entity-ref>.</text>
								</clause>
                <clause id="HBD66F2023C2848EC9729B1777D4D70CA">
                  <enum>(ii)</enum>
                  <text>Four experts in
				vascular, molecular, or basic science.</text>
								</clause>
                <clause id="HC4360EDF11004CD0A33426DFF1EC1AC0">
                  <enum>(iii)</enum>
                  <text>Four
				representatives of the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7529">National Institutes of Health</cato:entity-ref>.</text>
								</clause>
              </subparagraph>
              <subparagraph id="H80C78FCD8C4448269E950A99F57CF225">
                <enum>(B)</enum>
                <header>Chair</header>
                <text>The
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall designate the Chair of the Committee from among its
				members.</text>
							</subparagraph>
              <subparagraph id="H707229E34D6A4964A3E4024BA70009A5">
                <enum>(C)</enum>
                <header>Interim
				members</header>
                <text display-inline="yes-display-inline">In place of the 4
				members otherwise required to be appointed under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Public Health Service Act/s:409K/ss:b/p:2/sp:A/cl:i" proposed="true">subparagraph (A)(i)</cato:entity-ref>, the
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> may appoint 4 experts in vascular, molecular, or basic science to
				serve as members of the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" value="HHT Coordinating Committee" entity-parent-id="7529" proposed="true">Committee</cato:entity-ref> during the period preceding designation and
				establishment of HHT Treatment Centers of Excellence under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Public Health Service Act/s:317U" proposed="true">section 317U</cato:entity-ref>.</text>
							</subparagraph>
              <subparagraph id="HF2AD3FDA732C4B02856FFF8B5D344EAD">
                <enum>(D)</enum>
                <header>Publication of
				names</header>
                <text>Not later than 30 days after the establishment of the
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" value="HHT Coordinating Committee" entity-parent-id="7529" proposed="true">Committee</cato:entity-ref>, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall publish the names of the Chair and members of
				the Committee on the Website of the Department of Health and Human
				Services.</text>
							</subparagraph>
              <subparagraph id="H7CDE3432A64D4CC1BD910F849EDBE32B">
                <enum>(E)</enum>
                <header>Terms</header>
                <text>The
				members of the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" value="HHT Coordinating Committee" entity-parent-id="7529" proposed="true">Committee</cato:entity-ref> shall each be appointed for a 3-year term and, at the
				end of each such term, may be reappointed.</text>
							</subparagraph>
              <subparagraph id="HD120899BF442476597C26ED42016D045">
                <enum>(F)</enum>
                <header>Vacancies</header>
                <text>A
				vacancy on the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" value="HHT Coordinating Committee" entity-parent-id="7529" proposed="true">Committee</cato:entity-ref> shall be filled by the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> in the same manner in
				which the original appointment was made.</text>
							</subparagraph>
            </paragraph>
            <paragraph commented="no" id="H1197197AFDD04AD7AA7239876DBAE432">
              <enum>(3)</enum>
              <header>Responsibilities</header>
              <text>The
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" value="HHT Coordinating Committee" entity-parent-id="7500" proposed="true">Committee</cato:entity-ref> shall develop and coordinate implementation of a plan to advance
				research and understanding of HHT by—</text>
							<subparagraph commented="no" id="HC527DA5599624E3F94CB3BF3B56A9832">
                <enum>(A)</enum>
                <text>conducting or
				supporting basic, translational, and clinical research on HHT across the
				relevant national research institutes, national centers, and offices of the
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7529">National Institutes of Health</cato:entity-ref>, including the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" value="National Heart, Lung, and Blood Institute" entity-parent-id="7529">National Heart, Lung, and Blood
				Institute</cato:entity-ref>; the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" value="National Institute of Neurological Disorders and Stroke" entity-parent-id="7529">National Institute of Neurological Disorders and Stroke</cato:entity-ref>; the
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" value="National Institutes of Diabetes and Digestive and Kidney Diseases" entity-parent-id="7529">National Institutes of Diabetes and Digestive and Kidney Diseases</cato:entity-ref>; the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" value="Eunice Kennedy Shriver National Institute of Child Health and Human Development" entity-parent-id="7529">Eunice
				Kennedy Shriver National Institute of Child Health and Human Development</cato:entity-ref>; the
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" value="National Cancer Institute" entity-parent-id="7529">National Cancer Institute</cato:entity-ref>; and the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" value="Office of Rare Diseases" entity-parent-id="7529">Office of Rare Diseases</cato:entity-ref>; and</text>
							</subparagraph>
              <subparagraph commented="no" id="HEC92CBF6275F41DC80976B82DCD7023E">
                <enum>(B)</enum>
                <text>conducting
				evaluations and making recommendations to the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref>, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7529">Director of the
				National Institutes of Health</cato:entity-ref>, and the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" value="National Cancer Institute" entity-parent-id="7529">Director of the National Cancer
				Institute</cato:entity-ref> regarding the prioritization and award of <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7529">National Institutes of
				Health</cato:entity-ref> research grants relating to HHT, including with respect to grants
				for—</text>
								<clause commented="no" id="H1B7B1037D82142E1B906367C34A94A95">
                  <enum>(i)</enum>
                  <text>expand
				understanding of HHT through basic, translational, and clinical research on the
				cause, diagnosis, prevention, control, and treatment of HHT;</text>
								</clause>
                <clause commented="no" id="H3E2E5A07CC2C4A408055F225D6783BF4">
                  <enum>(ii)</enum>
                  <text>training programs
				on HHT for scientists and health professionals; and</text>
								</clause>
                <clause commented="no" id="H5C7BC85F22BF40849E5842A591CF158B">
                  <enum>(iii)</enum>
                  <text>HHT genetic
				testing research to improve the accuracy of genetic testing.</text>
								</clause>
              </subparagraph>
            </paragraph>
          </subsection>
          <subsection id="HE11C8108426A4B26BF7A74319CE7ADA3">
            <enum>(c)</enum>
            <header>Definitions</header>
            <text display-inline="yes-display-inline">In this section:</text>
						<paragraph id="H1ED6705D6CEB42FFB2B845137B7CB7F6">
              <enum>(1)</enum>
              <text>The term
				<term>Committee</term> means the HHT Coordinating Committee established under
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Public Health Service Act/s:409K/ss:b" proposed="true">subsection (b)</cato:entity-ref>.</text>
						</paragraph>
            <paragraph id="H1515A42B6B60456CB816B932B9A5E7D6">
              <enum>(2)</enum>
              <text>The term
				<term>HHT</term> means hereditary hemorrhagic
				telangiectasia.</text>
						</paragraph>
          </subsection>
        </section>
        <after-quoted-block>.</after-quoted-block>
      </quoted-block>
		</section>
    <section id="H772533C86DC54C2B9FC045F5E1C44F2C">
      <enum>5.</enum>
      <header>Centers for
			 disease control and prevention</header>
      <text display-inline="no-display-inline">
        <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Public Health Service Act/t:III/pt:B">Part B of title III of the Public Health
			 Service Act</cato:entity-ref> is amended by inserting after <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
          <cato:entity-ref entity-type="act" value="Public Health Service Act/s:317T">section 317T</cato:entity-ref> (<external-xref legal-doc="usc" parsable-cite="usc/42/247b-22">
            <cato:entity-ref entity-type="uscode" value="usc/42/247b–22">42 U.S.C. 247b–22</cato:entity-ref>
          </external-xref>)</cato:entity> the
			 following:</text>
			<quoted-block display-inline="no-display-inline" id="HC8E04C293DB445ED8CC4DFA23A404495" style="OLC">
				<section id="HEE8491B014FA4F538E5F0A536436EA44">
          <enum>317U.</enum>
          <header>Hereditary
				hemorrhagic telangiectasia</header>
					<subsection id="H1A4149886AD2453D9B152542E0CCE1CD">
            <enum>(a)</enum>
            <header>In
				general</header>
            <text>With respect to hereditary hemorrhagic telangiectasia (in
				this section referred to as <quote>HHT</quote>), the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7523">Director of the Centers
				for Disease Control and Prevention</cato:entity-ref> (in this section referred to as the
				<quote>Director</quote>) shall carry out the following activities:</text>
						<paragraph id="H2CBB7A2FAF29401BA157CD20F02EFD9A">
              <enum>(1)</enum>
              <text>The conduct of
				population screening described in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Public Health Service Act/s:317U/ss:c" proposed="true">subsection (c)</cato:entity-ref>.</text>
						</paragraph>
            <paragraph id="HB10489AC71A1407ABB5075B752C37CBB">
              <enum>(2)</enum>
              <text>The identification
				and conduct of investigations to further develop and support guidelines for
				diagnosis of, and intervention for, HHT, including cost-benefit studies.</text>
						</paragraph>
            <paragraph id="H95252DD8761D4890BFD368A566A187BE">
              <enum>(3)</enum>
              <text>The development of
				a standardized survey and screening tool on family history.</text>
						</paragraph>
            <paragraph commented="no" id="H54AAE7D714BB4ADF852F450A201D1CB6">
              <enum>(4)</enum>
              <text display-inline="yes-display-inline">The establishment, in collaboration with a
				voluntary health organization representing HHT families, of an HHT resource
				center within the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7523">Centers for Disease Control and Prevention</cato:entity-ref> to provide
				comprehensive education on, and disseminate information about, HHT to health
				professionals, patients, industry, and the public.</text>
						</paragraph>
            <paragraph id="H9D4BA6D9ED724705BBD0B9FCB6AF8D4E">
              <enum>(5)</enum>
              <text>The conduct or
				support of public awareness programs in collaboration with medical, genetic,
				and professional organizations to improve the education of health professionals
				about HHT.</text>
						</paragraph>
          </subsection>
          <subsection id="H55BC8939E981428297DDC396E33BD196">
            <enum>(b)</enum>
            <header>Collaborative
				approaches</header>
            <text>The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7523">Director</cato:entity-ref> shall carry out this section through
				collaborative approaches within the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" value="National Center on Birth Defects and Developmental Disabilities" entity-parent-id="7523">National Center on Birth Defects and
				Developmental Disabilities</cato:entity-ref> and the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" value="Division for Heart Disease and Stroke Prevention" entity-parent-id="7523">Division for Heart Disease and Stroke
				Prevention of the Centers for Disease Control and Prevention</cato:entity-ref> with respect to
				clotting and bleeding disorders.</text>
					</subsection>
          <subsection id="H0DCB347C0AF34EA4B26839B8C441A6DD">
            <enum>(c)</enum>
            <header>Population
				screening</header>
            <text>In carrying out population screening under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Public Health Service Act/s:317U/ss:a/p:1" proposed="true">subsection
				(a)(1)</cato:entity-ref>, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7523">Director</cato:entity-ref> shall—</text>
						<paragraph id="H0F807D572EF741979741F7558A1D54E1">
              <enum>(1)</enum>
              <text>designate and
				provide funding for a sufficient number of HHT Treatment Centers of Excellence
				to improve patient access to information, treatment, and care by HHT
				experts;</text>
						</paragraph>
            <paragraph id="HBDEAA3A1847D4596A3C425F36919F156">
              <enum>(2)</enum>
              <text>conduct
				surveillance through a population study, supplemented by sentinel health care
				provider or center surveillance, and by administrative database analyses, as
				useful, to accurately identify—</text>
							<subparagraph id="id9C315954FD0544A3BE588F7A1F4EA36B">
                <enum>(A)</enum>
                <text>the prevalence of
				HHT; and</text>
							</subparagraph>
              <subparagraph id="IDbe653930be4a4105900830a7db7f0278">
                <enum>(B)</enum>
                <text>the prevalence of
				hemorrhagic and embolic stroke and brain abscess, resulting from HHT;</text>
							</subparagraph>
            </paragraph>
            <paragraph id="HF7E0863B33FA42138F41594135004365">
              <enum>(3)</enum>
              <text>include HHT
				screening questions in the Behavioral Risk Factor Surveillance System survey
				conducted by the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7523">Centers for Disease Control and Prevention</cato:entity-ref> in order to screen
				a broader population and more accurately determine the prevalence of
				HHT;</text>
						</paragraph>
            <paragraph id="IDf7ba86af441c44349c0ef5e31cbe938f">
              <enum>(4)</enum>
              <text>provide data
				collected under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Public Health Service Act/s:317U/ss:c/p:2/sp:B" proposed="true">paragraph (2)(B)</cato:entity-ref> to the Paul Coverdell National Acute Stroke
				Registry, to facilitate—</text>
							<subparagraph id="idBA9A5501EED1420283FA6B6426C657F1">
                <enum>(A)</enum>
                <text>analyses of the
				natural history of hemorrhagic and embolic stroke in HHT; and</text>
							</subparagraph>
              <subparagraph id="id679AC892BC9C4C59879221EC1450A833">
                <enum>(B)</enum>
                <text>the development
				of screening and artery-vein malformation treatment guidelines specific to
				prevention of complications from HHT;</text>
							</subparagraph>
            </paragraph>
            <paragraph id="HDF94053073134216829F60F569B30A85">
              <enum>(5)</enum>
              <text display-inline="yes-display-inline">develop and implement programs, targeted
				for physicians and health care professional groups likely to be accessed by
				families with HHT, to increase HHT diagnosis and treatment rates through
				the—</text>
							<subparagraph id="HFB858F94EEB2417F9F31ECB5751E4980">
                <enum>(A)</enum>
                <text>establishment of a
				partnership with HHT Treatment Centers of Excellence designated under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Public Health Service Act/s:317U/ss:c/p:1" proposed="true">paragraph
				(1)</cato:entity-ref> through the creation of a database of patients assessed at such HHT
				Treatment Centers of Excellence (including with respect to phenotype
				information, genotype information, transfusion dependence, and radiological
				findings);</text>
							</subparagraph>
              <subparagraph commented="no" id="H14B0EBCDF5234F4CA3A2B6FA75CD5587">
                <enum>(B)</enum>
                <text>integration of
				such database with—</text>
								<clause commented="no" id="id9935E2585A054796AA228AF3CF373A7C">
                  <enum>(i)</enum>
                  <text>the universal
				data collection system used by the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7523">Centers</cato:entity-ref> for monitoring hemophilia with the
				blood disorders; and</text>
								</clause>
                <clause commented="no" id="idDE6C721D9E9D451BBB17CA29D6FEB360">
                  <enum>(ii)</enum>
                  <text>the Paul
				Coverdell National Acute Stroke Registry; and</text>
								</clause>
              </subparagraph>
              <subparagraph id="H05811EC0747E4CAF80BC5FC503C71983">
                <enum>(C)</enum>
                <text>inclusion of other
				medical providers who treat HHT patients; and</text>
							</subparagraph>
            </paragraph>
            <paragraph id="H8503AC1BA41E4351AD62A0FE5DEB3E70">
              <enum>(6)</enum>
              <text>use existing
				administrative databases on non-HHT Treatment Center of Excellence
				patients—</text>
							<subparagraph id="idA75639C4B80043B3B1C1641098FF0E5A">
                <enum>(A)</enum>
                <text>to learn about
				the natural history of HHT and the efficacy of various treatment modalities;
				and</text>
							</subparagraph>
              <subparagraph id="id79C24463B5784BEAA4B1820ECD8AD0FD">
                <enum>(B)</enum>
                <text>to better inform
				and develop screening and treatment guidelines associated with improvement in
				health care outcomes, and research priorities relevant to HHT.</text>
							</subparagraph>
            </paragraph>
          </subsection>
          <subsection id="HC9C7C6F2AA0B4B74A0BCD5C1EACE30CC">
            <enum>(d)</enum>
            <header>Eligibility for
				designation as HHT Treatment Center of Excellence</header>
            <text display-inline="yes-display-inline">In carrying out <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Public Health Service Act/s:317U/ss:c/p:1" proposed="true">subsection (c)(1)</cato:entity-ref>, the
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7523">Director</cato:entity-ref> may designate as an HHT Treatment Center of Excellence an academic
				health center demonstrating each of the following:</text>
						<paragraph id="H2D7A33860EE74954B433E16B72BC6B4F">
              <enum>(1)</enum>
              <text>The academic
				health center possesses a team of medical experts capable of providing
				comprehensive evaluation, treatment, and education to individuals with known or
				suspected HHT and their health care providers.</text>
						</paragraph>
            <paragraph id="HDA3706ABC95A4599901BA372A0BA170B">
              <enum>(2)</enum>
              <text>The academic
				health center has sufficient personnel with knowledge about HHT, or formal
				collaboration with one or more partnering organizations for personnel or
				resources, to be able to—</text>
							<subparagraph id="HFD327FDAC16C4B2FBFE2AB44C07D024E">
                <enum>(A)</enum>
                <text>respond in a
				coordinated, multidisciplinary way to patient inquiries; and</text>
							</subparagraph>
              <subparagraph id="HD64D4926F66A4519A904B6352A92C89E">
                <enum>(B)</enum>
                <text>coordinate
				evaluation, treatment, and education of patients and their families in a timely
				manner.</text>
							</subparagraph>
            </paragraph>
            <paragraph id="H34B6C8159DE646C682FA821EE8108590">
              <enum>(3)</enum>
              <text>The academic
				health center has the following personnel, facilities, and patient
				volume:</text>
							<subparagraph id="H2315B1CB01324869862C76C4D6040C3D">
                <enum>(A)</enum>
                <text>A medical director
				with—</text>
								<clause id="H14A6184F69A74EF7BF44110829E443BA">
                  <enum>(i)</enum>
                  <text>specialized
				knowledge of the main organ manifestations of HHT; and</text>
								</clause>
                <clause id="H7AD0C1025A4A46D48E7CA536A86D9D22">
                  <enum>(ii)</enum>
                  <text>the ability to
				coordinate the multidisciplinary diagnosis and treatment of patients referred
				to the center.</text>
								</clause>
              </subparagraph>
              <subparagraph id="H842CD21C233C478DAD4EEB1D4CB10658">
                <enum>(B)</enum>
                <text>Administrative
				staff with—</text>
								<clause id="H9823B7FBD3964EB5BCFDA126C1A8E13E">
                  <enum>(i)</enum>
                  <text>sufficient
				knowledge to respond to patient inquiries and coordinate patient care in a
				timely fashion; and</text>
								</clause>
                <clause id="HD13232764A5B4E84A4989FB763E9D76F">
                  <enum>(ii)</enum>
                  <text>adequate
				financial support to allow the staff to commit at least 25 to 50 percent of
				their time on the job to HHT.</text>
								</clause>
              </subparagraph>
              <subparagraph id="H38D3AF2E31C54545829D41C1F7ECE54B">
                <enum>(C)</enum>
                <text>An
				otolaryngologist with experience and expertise in the treatment of recurrent
				epistaxis in HHT patients.</text>
							</subparagraph>
              <subparagraph id="H21C0DC8E69C04E53BE91B291C4B59FC1">
                <enum>(D)</enum>
                <text>An interventional
				radiologist with experience and expertise in the treatment of pulmonary
				arteriovenous malformations (AVM).</text>
							</subparagraph>
              <subparagraph id="HA8EB2210D4934049AD11AFCA98DF1BCA">
                <enum>(E)</enum>
                <text>A genetic
				counselor or geneticist with the expertise to provide HHT-specific genetic
				counseling to patients and families.</text>
							</subparagraph>
              <subparagraph id="HB9F75845AAED43B884D43315ABCB7369">
                <enum>(F)</enum>
                <text>On-site facilities
				to screen for all major organ manifestations of HHT.</text>
							</subparagraph>
              <subparagraph id="H5174D804CDAD46139B10AB85151EB2F4">
                <enum>(G)</enum>
                <text>A patient volume
				of at least 25 new HHT patients per year.</text>
							</subparagraph>
              <subparagraph id="HB0521201C3A2479DA4B49B71DF9A0D54">
                <enum>(H)</enum>
                <text>Established
				mechanisms to coordinate surveillance and outreach with HHT patient advocacy
				organizations.</text>
							</subparagraph>
            </paragraph>
          </subsection>
        </section>
        <after-quoted-block>.</after-quoted-block>
      </quoted-block>
		</section>
    <section id="H6CAC7400DE4C486E9A6629A1CA3DC436">
      <enum>6.</enum>
      <header>Additional health
			 and human services activities</header>
      <text display-inline="no-display-inline">With respect to hereditary hemorrhagic
			 telangiectasia (referred to in this section as <quote>HHT</quote>), the
			 <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary of Health and Human Services</cato:entity-ref>, acting through the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7530">Administrator of the
			 Centers for Medicare &amp; Medicaid Services</cato:entity-ref>, shall award grants on a
			 competitive basis—</text>
			<paragraph commented="no" id="H20B2F29EE9FC4533A89F2992F8B2E3C0">
        <enum>(1)</enum>
        <text>for an analysis by
			 grantees of the Medicare Provider Analysis and Review (MEDPAR) file to develop
			 preliminary estimates from the Medicare program under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Social Security Act/t:XVIII">title XVIII of the Social
			 Security Act</cato:entity-ref> for—</text>
				<subparagraph commented="no" id="idB3263A0154FA4EFB8CBBA321E9793C80">
          <enum>(A)</enum>
          <text>preventable costs
			 of annual health care expenditures associated with untreated HHT furnished to
			 individuals with HHT, including items, services, and treatments; and</text>
				</subparagraph>
        <subparagraph commented="no" id="id7F551D03B7DB491DB0B4EA59FDE1527C">
          <enum>(B)</enum>
          <text>socioeconomic
			 costs associated with preventable medical events among individuals with HHT who
			 are entitled to benefits under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Social Security Act/t:XVIII/pt:A">part A of title XVIII of the Social Security Act</cato:entity-ref>
			 or enrolled under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Social Security Act/t:XVIII/pt:B">part B of such title</cato:entity-ref>, such as disability expenditures;
			 and</text>
				</subparagraph>
      </paragraph>
      <paragraph commented="no" id="H83C3A3E7F25E46D2B3089D1E091E4271">
        <enum>(2)</enum>
        <text>to make
			 recommendations regarding an enhanced data collection protocol to permit a more
			 precise determination of the total costs described in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Hereditary Hemorrhagic Telangiectasia Diagnosis and Treatment Act of 2013/s:6/p:1" proposed="true">paragraph (1)</cato:entity-ref>.</text>
			</paragraph>
    </section>
    <section id="HDFA86DFA42804E0190CEA89022B9934B">
      <enum>7.</enum>
      <header>Authorization of
			 appropriations</header>
			<subsection id="H714FE0E54D0F4A81AC47292014DA7695">
        <enum>(a)</enum>
        <header>In
			 general</header>
        <text>
          <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="auth-auth-approp">
            <cato:property name="purpose">To carry out <cato:entity-ref entity-type="act" value="Public Health Service Act/s:409K" proposed="true">section 409K of the Public Health Service
			 Act</cato:entity-ref> as added by <cato:entity-ref entity-type="act" value="Hereditary Hemorrhagic Telangiectasia Diagnosis and Treatment Act of 2013/s:4" proposed="true">section 4 of this Act</cato:entity-ref>, <cato:entity-ref entity-type="act" value="Public Health Service Act/s:317U" proposed="true">section 317U of the Public Health
			 Service Act</cato:entity-ref> as added by <cato:entity-ref entity-type="act" value="Hereditary Hemorrhagic Telangiectasia Diagnosis and Treatment Act of 2013/s:5" proposed="true">section 5 of this Act</cato:entity-ref>, and <cato:entity-ref entity-type="act" value="Hereditary Hemorrhagic Telangiectasia Diagnosis and Treatment Act of 2013/s:6" proposed="true">section 6 of this Act</cato:entity-ref>
            </cato:property>, there
			 is authorized to be appropriated <cato:funds-and-year amount="5000000" year="2014, 2015, 2016, 2017, 2018">$5,000,000 for each of fiscal years 2014
			 through 2018</cato:funds-and-year>.</cato:entity>
        </text>
			</subsection>
      <subsection id="H35B57AF30BA04CF3863C41BE09387CAB">
        <enum>(b)</enum>
        <header>Resource
			 center</header>
        <text>Of the amount authorized to be appropriated under
			 <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Hereditary Hemorrhagic Telangiectasia Diagnosis and Treatment Act of 2013/s:7/ss:a" proposed="true">subsection (a)</cato:entity-ref> for each of fiscal years 2014 through 2018, $1,000,000 shall be
			 for carrying out <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Public Health Service Act/s:317U/ss:a/p:4" proposed="true">section 317U(a)(4) of the Public Health Service Act</cato:entity-ref>, as added
			 by <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Hereditary Hemorrhagic Telangiectasia Diagnosis and Treatment Act of 2013/s:5" proposed="true">section 5 of this Act</cato:entity-ref>.</text>
			</subsection>
    </section>
  </legis-body>
</bill>
</doc>